Drugs / C-188-9
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05845307 | Jun → Nov 2025 | head and neck squamous cell carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06141031 | Jan 2024 → Jun 2029 expected | pancreatic ductal adenocarcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05384119 | Jan 2023 → May 2024 | breast cancer | Tvardi Therapeutics, Incorporated | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03195699 | Nov 2017 → Jun 2024 | breast cancer, colorectal cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma +3 | Tvardi Therapeutics, Incorporated | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05668949 | Sep 2025 | head and neck squamous cell carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05440708 | Mar 2023 → Feb 2027 expected | hepatocellular carcinoma | Tvardi Therapeutics, Incorporated | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05671835 | May 2023 → Aug 2025 | idiopathic pulmonary fibrosis | Tvardi Therapeutics, Incorporated | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | Tvardi Therapeutics, Incorporated | Results New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) tvarditherapeutics.com ↗
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology |
| 2026-01-08 | Tvardi Therapeutics, Incorporated | Results Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference tvarditherapeutics.com ↗
These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmonary function, further supporting the impact of TTI-101 on the inhibition of STAT3 in fibrosis and inflammation. |
| 2026-01-08 | Tvardi Therapeutics, Incorporated | Results Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights tvarditherapeutics.com ↗
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | Tvardi Therapeutics, Incorporated | New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) tvarditherapeutics.com ↗ |
| 2026-01-08 | Tvardi Therapeutics, Incorporated | Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference tvarditherapeutics.com ↗ |
| 2026-01-08 | Tvardi Therapeutics, Incorporated | Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights tvarditherapeutics.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-188-9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3392776 ↗ |
| Known as | Stat3 inhibitor c188-9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3392776 ↗ |
| Known as | Stat3 inhibitor tti-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3392776 ↗ |
| Known as | TTI-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03195699 ↗ |
| Action | Inhibit | “direct inhibitor of STAT3” NCT03195699 ↗ |
| Modality | Small molecule | “a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription 3” PMID 39792482 ↗ Mar 2025 |
| Route | Oral | “Patients were treated with TTI-101 orally twice daily” PMID 39792482 ↗ Mar 2025 |
| Target | STAT3 | “a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription 3” PMID 39792482 ↗ Mar 2025 |